NCT06169059View on ClinicalTrials.gov

To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

November 8, 2023

Study Completion Date

November 19, 2023

Conditions
Healthy Adult
Interventions
DRUG

JLP-2004

administration of JLP-2004(COX-2 inhibitor)

DRUG

JC-013

administration of JC-013(COX-2 inhibitor))

Trial Locations (1)

08779

H plus Yangji Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY